معرفی
Emily Hobson is a Lecturer in Pharmacology at the School of Chemistry, Pharmacy and Pharmacology, University of East Anglia (UEA), where she also earned her BSc in Pharmacology and Drug Discovery in 2019. She completed her PhD in cancer biology at UEA's School of Pharmacy, focusing on the transcription factor Nrf2 in lung and melanoma cancers. She has held prior teaching positions as Lecturer in Cell Biology and Immunology at UEA before moving to her current role in 2024.
Education:
- Bachelor of Science in Pharmacology and Drug Discovery, University of East Anglia (2019)
Her primary research interests lie in cancer biology and inflammation, with a focus on identifying and validating novel drug targets and understanding dysregulated signaling pathways in cancer. She is also actively involved in pedagogical research, having achieved Fellowship of the Higher Education Academy in 2024, reflecting her commitment to teaching excellence.
While no publications are listed in the provided text, her work appears to bridge translational pharmacology and cancer therapeutics, as evidenced by her research project on cancer medicines development. Her professional engagement suggests a strong interdisciplinary and educational focus.
Scientific and Professional Affiliations:
- Chair, Early Career Pharmacologists Advisory Group (ECPAG), British Pharmacological Society (2022–2024)
- Member, Early Career Pharmacologists Advisory Group (ECPAG), British Pharmacological Society (2022–present)
- Early Career Representative, Norwich Cancer Research Network (2020–present)
Emily serves as the Outreach and Engagement Officer for her School and is the module organiser for PHAP6015B. She led a research project funded by the British Pharmacological Society titled Cancer medicines: From the laboratory to the patient (Jan–Feb 2023), indicating active engagement in both research and public communication of science.
She is involved in team-based cancer research networks and contributes to institutional and national initiatives supporting early-career pharmacologists. Her future work is likely to expand on targeted cancer therapies and innovative teaching methods in pharmacology.
